AzTrials
AzTrials

Regional AnesthesiaPhase 4NESPNCT04338984

Nociception-directed Erector Muscle Spinae Plane Block in Open Heart Surgery

A Phase 4 study testing General anesthetic and Ropivacaine 0.5% Injectable Solution in people with Regional Anesthesia and Heart Surgery, run by Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu at 1 site in Romania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

With the advent of ultrasound (US) guidance, use of regional anaesthesia (RA) is poised to grow and evolve. Recently, cardiac surgery has benefited from newer US guided interfascial techniques as they promise to fulfil all the prerequisites of an enhanced recovery after surgery (ERAS) strategy(1,2). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Regional Anesthesia, Heart Surgery
What is being tested?
General anesthetic and Ropivacaine 0.5% Injectable Solution
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
86 participants
Where
1 siteRomania
Study dates
1 Dec 2019to 31 May 2021
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed Consent.
  • Elective heart surgery with sternotomy and bypass.
  • Hemodynamic stability prior to induction (no chest pain, SAP > 100 mmHg, MAP ≥ 60 mmHg, 50 < HR < 100 bpm).
  • Sinus rhythm.

Who cannot join

  • Known allergy to any of the medications used in the study.
  • BMI > 35.
  • Patient refusal to participate in the study.
  • Coagulopathy (INR > 1.5, APTT > 45, Fibrinogen < 150 mg/dl).
  • Non-elective/emergent and/or redo surgery.
  • ASA ≥ 4.
Show all 9Show fewer
  • Any preoperative hemodynamic support (mechanical or pharmaceutical).
  • Severe LV dysfunction (LVEF ≤ 30%).
  • Severe RV dysfunction or PHT (RVFAC ≤ 25%).

Trial locations and contacts

1 site in 1 country.

Romania1 site
  • Prof Dr CC Iliescu Institute for Emergency Cardiovascular Diseases

    Bucharest, 022328

Other trials in Romania

About this study

Official title: Combined Erector Muscle Spinae Plane Block and General Anaesthesia Versus General Anaesthesia Alone - Effect on Perioperative Opioid Consumption in Open Heart Surgery

With the advent of ultrasound (US) guidance, use of regional anaesthesia (RA) is poised to grow and evolve. Recently, cardiac surgery has benefited from newer US guided interfascial techniques as they promise to fulfil all the prerequisites of an enhanced recovery after surgery (ERAS) strategy(1,2).

The erector spinae plane (ESP) block represents such an alternative(3). Speed and ease of performance are paramount to encourage spread of its use. Hence, the scope of this trial is to investigate the effects on perioperative opioid consumption and several other secondary outcomes of a minimalist approach encompassing a bilateral single shot ESP block when applied as an adjunct to general anaesthesia.

Read the detailed description

DETAILED DESCRIPTION OF STUDY

  1. Ethics

Local Ethics Committee approval and Informed Consent from patient or next-of-kin are obtained prior to study enrolment.

  1. Study enrolment

Eighty adult patients scheduled for elective open cardiac surgery under general anaesthesia (GA) are randomly allocated to receive either GA plus ESP block (ESP group, n = 40) or GA alone (control group, n = 40).

  1. Methods - Preinduction
  2. Premedication with intramuscular morphine 0.1mg/kg 30 minutes before induction.
  3. 16-G peripheral intravenous cannula and radial artery catheter.
  4. Five-lead ECG, pulse oximetry, non-invasive and invasive blood pressure monitoring.
  5. Analgesia monitor - the NoL index (PMD200TM, Medasense) finger probe will be connected to the index finger of the non-cannulated hand.
  6. Surgical antibiotic prophylaxis (Cefuroxime 1.5g)
  7. Stress ulcer prophylaxis (omeprazole 40 mg)
  8. Methods - ESP block (intervention group only)

Before induction, patients in the intervention group are placed in sitting position under the close supervision of the attending nurse anaesthetist. After skin asepsis with chlorhexidine 2%, a high-frequency linear ultrasound probe is positioned parasagittally, 2-3 cm from midline, bilaterally, at the level of the T5 transverse process. A 25-G echogenic block needle is inserted at 20⁰-30⁰ in a caudal-to-cephalad direction until the tip of the needle reaches the interfascial plane between the erector spinae muscle and the inter-transverse ligaments. Correct hydrodissection at T5 level is first certified using normal saline. Subsequently, ropivacaine 0.5% with dexamethasone 8mg/20ml is used and maximum spread is attained by slowly advancing the needle as the interfascial plane splits up ahead. A maximum dose of 3mg/kg ropivacaine is used, corresponding to 1.5 mg/kg per side (e.g., 20 ml ropivacaine 0.5% / side for a 70kg adult). Supine position is resumed after completion of block.

  1. Methods - General anaesthesia
  2. End tidal CO2 (ETCO2).
  3. Bispectral index (BIS) monitoring of hypnotic depth (target 40-60).
  4. The nociception monitor (PMD200TM, Medasense) is started after induction of general anaesthesia; a calibration period of 1-2 minutes is usually required.
  5. CVP insertion into the right internal jugular vein under ultrasound guidance. Any other hemodynamic monitor deemed useful is left at the discretion of the treating anaesthetist.
  6. Urinary catheter, rectal temperature probe placement.
  7. Intubating conditions 6.1. Propofol 1-1.5 mg/kg or Etomidate 0.2-0.3 mg/kg. 6.2. Fentanyl 5 mcg/kg. 6.3. Atracurium 0.5 mg/kg.
  8. Maintenance of anaesthesia

7.1. Sevoflurane in O2 during periods of preserved pulmonary blood flow and mechanical ventilation according to BIS (see target above).

7.2. Propofol infusion according to BIS (see target above) during periods of extracorporeal support.

7.3. Atracurium 0.2-0.3 mg/kg/h for adequate neuromuscular blockade.

7.4. Management of analgesia divides in:

7.4.1. Analgesia support

7.4.1.1. ESP block in the intervention group only:

  • Theoretical duration of ESP block with surgical intensity is 4-6 hours.

7.4.1.2. Fentanyl (both study groups):

  • Analgesia monitoring (see below) provides feedback to its administration.
  • Administration follows a combination of continuous infusion and bolus dosing according to our local protocol:
  • Fentanyl 1.5 mg/50ml (30 mcg/ml).
  • Bolus dose (ml): Weight/20, which is equivalent to 1.5 mcg/kg.
  • Infusion rate (ml/hour): Weight/10, which is equivalent to 3 mcg/kg/h.
  • Last infusion rate before large vessel cannulation is maintained throughout the bypass period.

7.4.1.3. Paracetamol (both study groups):

  • Administration of 2 grams following induction of general anaesthesia.

7.4.2. Analgesia monitoring

7.4.2.1. NoL index provides a multiderivative assessment of nociception before large vessel cannulation; depending on the spontaneous cardiac rhythm, it may be expected to continue reflecting nociception even after completion of extracorporeal circulation.

  • Optimal analgesia is defined as a NoL index of 10-25.
  • Allow periods of fluctuation of less than 1 minute.
  • After sternotomy, allow a maximum fluctuation interval of 3 minutes before vital data are gathered.
  • In the ESP group, if NOL target is attained, stop fentanyl administration.

7.4.2.2. Ancillaries such as mean arterial blood pressure (MAP) and heart rate (HR) provide complementary decision loops: targets are within ± 20% of preoperative baseline.

  • During CBP they provide the only feedback on adequacy of analgesia, although highly unspecific.
  • May be used at any time to complement the NoL index.
  1. Methods - Postoperatively
  2. Criteria to be met before extubation: 1.1. Normothermia (T◦ ≥ 36◦C). 1.2. No clinical bleeding. 1.3. Wakefulness and RASS [-1;1]. 1.4. Hemodynamic stability with minimal vasoactive support (dobutamine < 5 µg/kg/min and norepinephrine < 100 ng/kg/min): 1.4.1. MAP ≥ 60 mmHg 1.4.2. Lactate ≤ 2 mmol/L 1.4.3. Preserved flow (CI ≥ 2.2L/min/m2) assessed by: 1.4.3.1. TTE any time after ICU admission 1.4.3.2. TOE only before extubation, regardless of patient location 1.5. Respiratory: 1.5.1. Adequate gas exchange: 1.5.1.1. Normocarbia. 1.5.1.2. PaO2/FiO2 ≥ 250. 1.5.2. Adequate effort: 1.5.2.1. Tidal volume ≥ 5 ml/kg. 1.5.2.2. Negative inspiratory force ≤ -20 cmH2O. 1.5.3. Adequate airway reflex to handle secretions.
  3. Management of analgesia divides in:

2.1. Analgesia support:

2.1.1. Paracetamol 1g iv 6 hourly is standard in both groups.

2.1.2. Morphine bolus doses of 0.03 mg/kg in combination with continuous iv morphine 0.03 mg/kg/h as elicited by nociception monitoring (see below).

2.2. Analgesia monitoring

2.2.1. The visual analogue scale (VAS) is used to provide feedback on adequacy of analgesia.

2.2.2. If VAS > 3, then provision of a combination of paracetamol and morphine is warranted (see above).

Being tested
General anesthetic, Ropivacaine 0.5% Injectable Solution
Keywords
erector spinae plane block, fast-track, rehabilitation, opioid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • General anestheticDrug

    Also called Fentanyl based general anaesthesia

    Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.

  • Ropivacaine 0.5% Injectable SolutionDrug

    Also called Erector Spinae Plane Block

    Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.

    Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%.

Study groups in NCT04338984
Study groupRoleWhat they receive
General anesthesia alone (AG)Active comparatorOpioid based analgesia: Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline). Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol.
Receives: Drug: General anesthetic
Erector Spinae Plane Block and General Anaesthesia (ESPAG)ExperimentalBilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision. Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline). Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol.
Receives: Drug: Ropivacaine 0.5% Injectable Solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative fentanyl consumption (µg/kg/h)

    Goal directed monitoring of nociception with NOL index PMD200 (+/- variation of mean arterial blood pressure and heart rate)

    Measured: during intraoperative period

Secondary outcomes (12)
  1. Fentanyl (µg/kg/h) consumption

    Goal directed monitoring of nociception with NOL index PMD200

    Measured: until large vessel cannulation

  2. Morphine consumption (mg/kg)

    Postoperative opioid administration

    Measured: 24 hours and 48 hours after surgery

  3. Quality of postoperative analgesia

    Assessment - visual analog scale (VAS) (minimum of 0, maximum of 10)

    Measured: 6 hours, 12 hours, 24 hours and 48 hours after extubation/ICU admission and 1 hour after drain removal

  4. Time to extubation

    Following ICU admission, the time it takes to extubate the patient safely

    Measured: up to 24 hours after surgery

  5. Norepinephrine dose (mcg/kg/h)

    Cumulative dose of Norepinephrine

    Measured: intraoperative, 6 hours and 12 hours after surgery

  6. Time to catecholamine - free state

    Following ICU admission, the time it takes to stop all catecholamines.

    Measured: up to 96 hours after surgery

  7. Rate of postoperative pneumonia

    Postoperative incidence

    Measured: up to two weeks

  8. Rate of atrial fibrillation

    Postoperative incidence

    Measured: 48 hours after ICU admission

  9. Time to first out of bed

    Measured: up to 72 hours after surgery

  10. Rate of nausea and vomiting (PONV)

    Measured: 24 hours after ICU admission

  11. Rate of delirium

    Measured: 7 days after surgery

  12. Time to removal of drain

    Measured: up to 72 hours after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2020
  2. Study start1 Dec 2019
  3. Primary completion30 Apr 2021
  4. Study completion31 May 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
86 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04338984
Sponsor's protocol ID
18750
Acronym
NESP
Status last verified
Aug 2022
First submitted
2 Apr 2020
Last updated
12 Aug 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Smith LM, Barrington MJ; St Vincent's Hospital, Melbourne. Ultrasound-guided blocks for cardiovascular surgery: which block for which patient? Curr Opin Anaesthesiol. 2020 Feb;33(1):64-70. doi: 10.1097/ACO.0000000000000818.

    PubMed 31833864
  • Kelava M, Alfirevic A, Bustamante S, Hargrave J, Marciniak D. Regional Anesthesia in Cardiac Surgery: An Overview of Fascial Plane Chest Wall Blocks. Anesth Analg. 2020 Jul;131(1):127-135. doi: 10.1213/ANE.0000000000004682.

    PubMed 32032103
  • Macaire P, Ho N, Nguyen T, Nguyen B, Vu V, Quach C, Roques V, Capdevila X. Ultrasound-Guided Continuous Thoracic Erector Spinae Plane Block Within an Enhanced Recovery Program Is Associated with Decreased Opioid Consumption and Improved Patient Postoperative Rehabilitation After Open Cardiac Surgery-A Patient-Matched, Controlled Before-and-After Study. J Cardiothorac Vasc Anesth. 2019 Jun;33(6):1659-1667. doi: 10.1053/j.jvca.2018.11.021. Epub 2018 Nov 19.

    PubMed 30665850

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing General anesthetic and Ropivacaine 0.5% Injectable Solution in people with Regional Anesthesia and Heart Surgery, run by Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu at 1 site in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative fentanyl consumption (µg/kg/h) (time frame: during intraoperative period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04338984, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in